Validation of serum paraoxonase/arylesterase 1 (PON1) as a protein marker of illicit dexamethasone treatment in veal calves

被引:1
|
作者
Guglielmetti, Chiara [1 ]
Brusadore, Sonia [1 ]
Pezzolato, Marzia [1 ]
Baioni, Elisa [1 ]
Ingravalle, Francesco [1 ]
Acutis, Pier Luigi [1 ]
Mazza, Maria [1 ]
Bozzetta, Elena [1 ]
机构
[1] Ist Zooprofilatt Sperimentale Piemonte Liguria &, Turin, Italy
关键词
Dexamethasone; veal calves; anabolic treatments; paraoxonase; PON1; 2D electrophoresis; marker; PLASMA-PROTEIN; BIOMARKER; CATTLE; URINE; ABUSE;
D O I
10.1080/19440049.2022.2062057
中图分类号
O69 [应用化学];
学科分类号
081704 ;
摘要
The illicit use of dexamethasone and other glucocorticoids for cattle fattening in livestock production has been widely described; evidence for illegal treatments can be obtained by direct or indirect detection. In our previous study, we applied two-dimensional electrophoresis (2DE) to identify plasma protein markers of dexamethasone administration in veal calves. Comparison of 2DE maps obtained from blood samples before and after treatment showed the disappearance of two protein spots identified as serum paraoxonase/arylesterase 1 precursor (PON1). In the present study, we validated PON1 as a marker by analysing a larger number of samples treated with dexamethasone for illicit use. Analysis of samples from experimental treatment with other glucocorticoids, androgens and oestrogens confirmed that their influence on PON1 could be excluded. The specificity of the PON1 protein marker was verified on expected negative field samples to exclude interfering factors. However, there is poor statistical evidence to support a significant association between the outcome of PON1 and the considered variables. The results on field samples were compared with histological examination of the thymus as a biomarker of corticosteroid treatment monitored in the Italian histological plan for the control of growth promoters in animals. Two suspect cases were identified from two Piedmont farms where other animals had tested positive at histological examination. In conclusion, the absence of PON1 in the plasma of veal calves can indirectly reveal illicit dexamethasone treatment in individual animals and so identify suspect farms for further investigation. It is effective in a period ranging from 3 to about 10 days from illicit treatment, covering a time span that goes beyond the limits of official chemical controls and preceding histological controls on the thymus of slaughtered animals. PON1 detection in plasma can be coupled with other tests to identify illegal dexamethasone use on veal calf farms.
引用
收藏
页码:1065 / 1073
页数:9
相关论文
共 50 条
  • [1] Paraoxonase 1 (PON1) is a valid plasma marker to detect illicit treatment with dexamethasone in veal calves
    Mazza, Maria
    Pezzolato, Marzia
    Guglielmetti, Chiara
    Brusadore, Sonia
    Botta, Mario
    Meistro, Serena
    Ingravalle, Francesco
    Baioni, Elisa
    Bozzetta, Elena
    Acutis, Pier Luigi
    TOXICOLOGY LETTERS, 2017, 280 : S296 - S296
  • [2] Paraoxonase and arylesterase activities of serum PON1 in young heal thy Bulgarian subjects
    Doneva-Basheva, Krastinka
    Vlaykova, T.
    EUROPEAN JOURNAL OF MEDICAL RESEARCH, 2011, 16 : 12 - 13
  • [3] The human serum paraoxonase arylesterase gene (PON1) is one member of a multigene family
    PrimoParmo, SL
    Sorenson, RC
    Teiber, J
    LaDu, BN
    GENOMICS, 1996, 33 (03) : 498 - 507
  • [4] Evaluation of paraoxonase and arylesterase activity of serum PON1 in patients with acute heart disease
    Yordanova, K.
    Emin, Sinan
    Doneva, Krastina
    Tsoneva, Vanya
    Dimov, Dimo
    Kamenova, Zdravka
    Vlaykova, Tatyana
    EUROPEAN JOURNAL OF MEDICAL RESEARCH, 2009, 14 : 122 - 123
  • [5] Serum paraoxonase 1 (PON1) measurement: an update
    Ceron, Jose J.
    Tecles, Fernando
    Tvarijonaviciute, Asta
    BMC VETERINARY RESEARCH, 2014, 10
  • [6] Serum paraoxonase 1 (PON1) measurement: an update
    Jose J Ceron
    Fernando Tecles
    Asta Tvarijonaviciute
    BMC Veterinary Research, 10
  • [7] Paraoxonase, arylesterase and lactonase activities of paraoxonase-1 (PON1) in obese and severely obese women
    Cervellati, Carlo
    Bonaccorsi, Gloria
    Trentini, Alessandro
    Valacchi, Giuseppe
    Sanz, Juana M.
    Squerzanti, Monica
    Spagnolo, Manuela
    Massari, Leo
    Crivellari, Ilaria
    Greco, Pantaleo
    Parladori, Roberta
    Passaro, Angelina
    Ricci, Giorgio
    SCANDINAVIAN JOURNAL OF CLINICAL & LABORATORY INVESTIGATION, 2018, 78 (1-2): : 18 - 24
  • [8] Identification of residues essential for human paraoxonase (PON1) arylesterase/organophosphatase activities
    Josse, D
    Xie, WH
    Renault, F
    Rochu, D
    Schopfer, LM
    Masson, P
    Lockridge, O
    BIOCHEMISTRY, 1999, 38 (09) : 2816 - 2825
  • [9] Serum paraoxonase PON1 and its interactions with HDL
    Gaidukov, Leonid A.
    Aharoni, Amir
    Khersonsky, Olga
    Tawfik, Dan S.
    FASEB JOURNAL, 2008, 22
  • [10] The effects of paraoxonase (PON1) polymorphisms in the coding region and environmental factors on serum PON1 activity
    Jintana, Sirivarasai
    Sming, Kaojarern
    Krongtong, Yoovathawom
    Thanyachai, Sura
    ANNALS OF NUTRITION AND METABOLISM, 2007, 51 : 112 - 112